The TG improved in BHR by 1 doubling dose ( dd ) ( 95 % CI 0.3 to 1.7 dd ) , and they experienced reduced interleukin 6 ( IL-6 ) and monocyte chemoattractant protein 1 ( MCP-1 ) and improved AQLQ and asthma exacerbation ( p < 0.05 ) .